Premium
After the approval of dupilumab for moderate‐to‐severe atopic dermatitis: what is next on the research agenda?
Author(s) -
Schmitt J.
Publication year - 2018
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.16505
Subject(s) - dupilumab , atopic dermatitis , medicine , dermatology , dermatologic agents , microbiology and biotechnology , biology , antibiotics
Linked Article: de Bruin‐Weller et al . Br J Dermatol 2018; 178 :1083–1101.